HK1208994A1 - Methods for making fully human bispecific antibodies using a common light chain - Google Patents
Methods for making fully human bispecific antibodies using a common light chain Download PDFInfo
- Publication number
- HK1208994A1 HK1208994A1 HK15109745.2A HK15109745A HK1208994A1 HK 1208994 A1 HK1208994 A1 HK 1208994A1 HK 15109745 A HK15109745 A HK 15109745A HK 1208994 A1 HK1208994 A1 HK 1208994A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- light chain
- bispecific antibodies
- methods
- chain variable
- fully human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/488,628 | 2012-06-05 | ||
| US13/488,628 US20130045492A1 (en) | 2010-02-08 | 2012-06-05 | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| PCT/US2013/044257 WO2013184761A1 (en) | 2012-06-05 | 2013-06-05 | Methods for making fully human bispecific antibodies using a common light chain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1208994A1 true HK1208994A1 (en) | 2016-03-24 |
Family
ID=48652344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15109745.2A HK1208994A1 (en) | 2012-06-05 | 2013-06-05 | Methods for making fully human bispecific antibodies using a common light chain |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2854523A1 (en) |
| JP (1) | JP2015525071A (en) |
| KR (1) | KR20150023535A (en) |
| CN (1) | CN104582476B (en) |
| AU (1) | AU2013271737A1 (en) |
| CA (1) | CA2874846A1 (en) |
| HK (1) | HK1208994A1 (en) |
| IL (1) | IL235781A0 (en) |
| MX (1) | MX2014014891A (en) |
| RU (1) | RU2014153674A (en) |
| SG (2) | SG10201609535TA (en) |
| WO (1) | WO2013184761A1 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| ES2603559T5 (en) | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Mouse common light chain |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| NZ730271A (en) | 2012-03-16 | 2022-09-30 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| CN104302170B (en) | 2012-03-16 | 2016-09-28 | 瑞泽恩制药公司 | Mice that produce antigen-binding proteins with pH-dependent binding properties |
| RS57118B1 (en) | 2012-03-16 | 2018-06-29 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
| PT2838917T (en) | 2012-04-20 | 2019-09-12 | Merus Nv | Methods and means for the production of heterodimeric ig-like molecules |
| TWI635098B (en) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | Antibodies comprising chimeric constant domains |
| CN105189545A (en) * | 2013-03-13 | 2015-12-23 | 瑞泽恩制药公司 | Common light chain mice |
| TWI701042B (en) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
| PT3221359T (en) | 2014-11-17 | 2020-06-23 | Regeneron Pharma | Methods for tumor treatment using cd3xcd20 bispecific antibody |
| EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| DK3221357T3 (en) * | 2014-11-20 | 2020-08-10 | Hoffmann La Roche | Common light chains and methods of use |
| JP6773679B2 (en) | 2015-03-30 | 2020-10-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Heavy chain constant region with reduced binding to the Fc gamma receptor |
| CA2984010A1 (en) | 2015-05-12 | 2016-11-17 | Regeneron Pharmaceuticals, Inc. | Multimeric protein purity determination |
| DK3353212T3 (en) * | 2015-09-23 | 2021-12-20 | Regeneron Pharma | Optimized bispecific anti-CD3 antibodies and uses thereof |
| TWI752920B (en) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | Antigen-binding proteins that activate the leptin receptor |
| CN108777951B (en) | 2016-01-13 | 2021-11-05 | 瑞泽恩制药公司 | Non-human animals having immunoglobulin heavy chain variable regions comprising engineered diversity clusters and uses thereof |
| SI3773713T1 (en) | 2018-04-06 | 2025-08-29 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of engineered dh-dh rearrangement and uses thereof |
| IL280875B2 (en) | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Cytokine release syndrome-attenuating dosing strategy for bispecific antibodies to CD3 and CD20 |
| WO2020102777A1 (en) * | 2018-11-16 | 2020-05-22 | Virtuoso Binco, Inc. | Cd38 and icam1 antibodies and uses thereof |
| BR112021016173A2 (en) | 2019-02-22 | 2021-11-03 | Regeneron Pharma | Genetically modified rodent, methods of producing a genetically modified rodent and producing an anti-nav1.7 antibody, isolated rodent cell or tissue, immortalized cell line, rodent embryo, targeting nucleic acid construct, and, hybridoma |
| KR20210095781A (en) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety |
| KR20230066386A (en) | 2020-09-11 | 2023-05-15 | 리제너론 파마슈티칼스 인코포레이티드 | Identification and production of antigen-specific antibodies |
| CA3199879A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| US12371487B2 (en) | 2020-12-23 | 2025-07-29 | Regeneron Pharmaceuticals, Inc. | Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same |
| CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| CN118496357A (en) * | 2023-02-15 | 2024-08-16 | 康源博创生物科技(北京)有限公司 | Polypeptide and antibody containing same as light chain |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341351C (en) * | 1988-09-06 | 2002-03-26 | Marc D. Better | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2161351C (en) * | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2005538706A (en) * | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ, | Super humanized antibody |
| ES2350248T3 (en) * | 2001-10-01 | 2011-01-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | PROCEDURE FOR THE PRODUCTION OF PROTEIN LIBRARIES AND THE SELECTION OF PROTEINS FROM THE SAME. |
| US20050095712A1 (en) * | 2002-01-17 | 2005-05-05 | Alberto Martin | Mutations caused by activation-induced cytidine deaminase |
| CN1675245B (en) * | 2002-06-14 | 2011-01-12 | 免疫医疗公司 | Humanized monoclonal antibody hPAM4 |
| CN101962408A (en) * | 2002-07-12 | 2011-02-02 | 杰斐逊·富特 | superhumanized antibody |
| PL3456190T3 (en) * | 2008-06-27 | 2022-06-06 | Merus N.V. | Antibody producing transgenic murine animal |
| ES2603559T5 (en) * | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Mouse common light chain |
| FI3865581T3 (en) * | 2011-08-05 | 2024-11-02 | Regeneron Pharma | Humanized universal light chain mice |
-
2013
- 2013-06-05 AU AU2013271737A patent/AU2013271737A1/en not_active Abandoned
- 2013-06-05 CN CN201380030014.1A patent/CN104582476B/en active Active
- 2013-06-05 CA CA2874846A patent/CA2874846A1/en not_active Abandoned
- 2013-06-05 RU RU2014153674A patent/RU2014153674A/en not_active Application Discontinuation
- 2013-06-05 EP EP13729875.8A patent/EP2854523A1/en not_active Ceased
- 2013-06-05 MX MX2014014891A patent/MX2014014891A/en unknown
- 2013-06-05 SG SG10201609535TA patent/SG10201609535TA/en unknown
- 2013-06-05 JP JP2015516160A patent/JP2015525071A/en active Pending
- 2013-06-05 WO PCT/US2013/044257 patent/WO2013184761A1/en not_active Ceased
- 2013-06-05 KR KR20147036869A patent/KR20150023535A/en not_active Withdrawn
- 2013-06-05 SG SG11201407644UA patent/SG11201407644UA/en unknown
- 2013-06-05 HK HK15109745.2A patent/HK1208994A1/en unknown
-
2014
- 2014-11-18 IL IL235781A patent/IL235781A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014014891A (en) | 2015-06-17 |
| CN104582476B (en) | 2017-03-08 |
| CA2874846A1 (en) | 2013-12-12 |
| SG11201407644UA (en) | 2014-12-30 |
| KR20150023535A (en) | 2015-03-05 |
| SG10201609535TA (en) | 2017-01-27 |
| JP2015525071A (en) | 2015-09-03 |
| IL235781A0 (en) | 2015-01-29 |
| AU2013271737A1 (en) | 2015-01-22 |
| CN104582476A (en) | 2015-04-29 |
| RU2014153674A (en) | 2016-07-27 |
| EP2854523A1 (en) | 2015-04-08 |
| WO2013184761A1 (en) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1208994A1 (en) | Methods for making fully human bispecific antibodies using a common light chain | |
| HK1218550A1 (en) | Common light chain mouse | |
| HK1205873A1 (en) | Common light chain mouse | |
| EP4218409A3 (en) | Mice expressing a limited immunoglobulin light chain repertoire | |
| WO2012148873A3 (en) | Non-human animals expressing antibodies having a common light chain | |
| MX379533B (en) | HUMANIZED UNIVERSAL LIGHT CHAIN MICE. | |
| WO2017132562A8 (en) | Antigen binding proteins that bind pd-l1 | |
| EP4491195A3 (en) | Bispecific tetravalent antibodies and methods of makiing and using thereof | |
| WO2014012085A3 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| MX2021009151A (en) | Antibodies and chimeric antigen receptors specific for ror1. | |
| MY172946A (en) | Restricted immunoglobulin heavy chain mice | |
| HK1218930A1 (en) | Novel multispecific constructs | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2013136186A3 (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
| NZ627977A (en) | Humanized rodents that express heavy chains containing vl domains | |
| WO2011127412A3 (en) | Soluble human st-2 antibodies and assays | |
| HK1200271A1 (en) | Mice that produce antigen-binding proteins with ph-dependent binding characteristics | |
| SG10201810825YA (en) | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same | |
| EA201500502A1 (en) | Binding HER3 ANTIGEN PROTEINS CONNECTING BETA HER3 BAT | |
| MX378944B (en) | HUMANIZED ANTI-TF ANTIGEN ANTIBODIES. | |
| EP3467498A4 (en) | Anti-human hemoglobin monoclonal antibody or antibody kit, insoluble carrier particle to which anti-human hemoglobin monoclonal antibody is immobilized, and measurement reagent and measurement method using same | |
| HK1192586A (en) | Humanized universal light chain mice |